Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676316 | 1.00 | MMP3 (0.36) | MMP3TGFBR1LMNACNR1ADRA1A | |
| SCHEMBL16372630 | 0.82 | CES2 (0.35) | MMP3TGFBR1MMP9 | |
| SCHEMBL16846024 | 0.82 | MMP1 (0.34) | MMP3TGFBR1LMNACNR1ADRA1A | |
| SCHEMBL7567693 | 0.82 | LMNA (0.33) | TGFBR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL20999419 | 0.81 | — | — | |
| SCHEMBL12311713 | 0.81 | — | — | |
| SCHEMBL13605043 | 0.80 | ECE1 (0.34) | MMP3 | |
| SCHEMBL14539228 | 0.80 | ECE1 (0.34) | MMP3 | |
| SCHEMBL22963792 | 0.79 | KDM4E (0.39) | MMP3KDM4EMMP9SMN1; SMN2 | |
| SCHEMBL12301639 | 0.79 | HDAC7 (0.37) | MMP3ADRA1ATDP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324190-B2 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-12-04 | — | — | US | disclosed |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | CCNY, CCND2, ETV6 | MMP3 3415/4885TGFBR1 4116/4885LMNA 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.